Novavax Inc. has released its financial results for the third quarter of 2026, reporting a total revenue of $68 million. This marks a significant achievement for the company as it raises its full-year guidance for total revenue to $400 million, reflecting a positive outlook for its operations.

The announcement comes as Novavax continues to strengthen its position in the biological products industry, which focuses on developing vaccines and therapeutics. The company has also highlighted its ongoing collaboration with Sanofi, which recently initiated a Phase 3 trial for a combination influenza-COVID-19 vaccine in Europe.

John C. Jacobs, President and Chief Executive Officer of Novavax, stated, "This quarter, we continued to execute across all three pillars of our strategy." He emphasized the importance of their partnership with Sanofi, which is expected to support future growth and innovation in vaccine development.

In addition to the revenue increase, Novavax has improved its guidance for combined research and development (R&D) and selling, general, and administrative (SG&A) expenses by $5 million at the midpoint. This reflects the company's commitment to managing costs effectively while pursuing its ambitious growth plans.

Novavax's recent achievements include earning a $125 million milestone payment from Sanofi upon the launch of the Phase 3 trial. The company is also preparing to advance its differentiated C. difficile vaccine program into clinical trials as early as 2027, showcasing its broad pipeline of vaccine candidates.

As Novavax continues to make strides in the biological products sector, industry competitors will be closely watching its progress, particularly in light of the ongoing collaboration with Sanofi. The company is also conducting multiple experiments with its proprietary Matrix-M adjuvant in various infectious disease targets and oncology models.

Looking ahead, Novavax is set to host a conference call to discuss its Q3 results and operational highlights further, providing investors and stakeholders with more insights into its future direction.

Details were not available in the SEC filing regarding specific next steps beyond this report.